Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
How soon after stopping a PARP inhibitor (due to disease progression), do you start IV cytotoxic chemo?
Patient with platinum sensitive disease, was on PARP for ~1 year prior to progression.
Related Questions
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?
Do you personally review all imaging you order or rely judiciously on radiologist interpretation?
What platform do you use for HRD testing of ovarian cancers and why?
Would you prescribe vaginal estrogen cream for vaginal dryness to a patient in her 40s with a history of stage IA granulosa cell tumor?
Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?
In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?